TY - JOUR T1 - Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00138-2022 VL - 8 IS - 3 SP - 00138-2022 AU - Elisa Franceschi AU - Nora Drick AU - Jan Fuge AU - Tobias Welte AU - Hendrik Suhling Y1 - 2022/07/01 UR - http://openres.ersjournals.com/content/8/3/00138-2022.abstract N2 - As eosinophil granulocytes are the main effector cells in patients suffering from bronchial asthma [1], the introduction of anti-interleukin (IL)-5 and IL-5 receptor antibodies therapy led to a substantial change in severe asthma treatment [2, 3]. Despite a correlation between eosinophils and response to antibody therapy, little data regarding biomarkers and predicting factors for treatment outcome are available [4]. As eosinophil blood levels are influenced by oral and inhaled steroid therapy, we assumed that the dosage of eosinophilic cationic protein (ECP) might be a better biomarker to predict therapy response.This study of the eosinophil cationic protein (ECP) as predictor of clinical response to biological therapy in severe asthma found that ECP is not useful in unselected patients but may have a role in those not exposed to oral corticosteroids. https://bit.ly/398RwEk ER -